Clinical Trials Logo

Clinical Trial Summary

This is a Phase 2, randomized, double-blind, vehicle-controlled study to assess the efficacy and safety of CLE-400 topical gel for the treatment of chronic pruritus in adult subjects with Notalgia Paresthetica (NP).


Clinical Trial Description

Study to assess the efficacy and safety of CLE-400 topical gel applied once daily for the treatment of moderate-severe chronic pruritus in adult subjects with NP. The study comprises a screening phase of up to 37 days, including a 7-day run-in period, a 4-week double-blind treatment period, and a 2-week follow-up period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06262607
Study type Interventional
Source Clexio Biosciences Ltd.
Contact Clinical Trial Manager
Phone 972-73-3318717
Email CLE400.Patients@clexio.com
Status Recruiting
Phase Phase 2
Start date January 29, 2024
Completion date January 15, 2025